Linked Life Data

20645688

Source:http://linkedlifedata.com/resource/pubmed/id/20645688

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
7
pubmed:dateCreated
2010-7-21
pubmed:abstractText
Romidepsin is a histone deacetylase inhibitor (HDI), approved by the US FDA for the treatment of cutaneous T-cell lymphoma (CTCL). Although various mechanisms have been proposed for the activity of HDIs, including induction of genes controlling cell cycle, acetylation of cytoplasmic proteins and direct induction of apoptosis, the mechanism underlying activity of romidepsin and other HDIs in CTCL is not known. Romidepsin induces long-lasting responses. The side-effect profile is similar to that of other HDIs, causing fatigue, nausea and thrombocytopenia. Management of the CTCL population requires vigilence to prevent infection with skin contaminants, and monitoring of potassium and magnesium, electrolytes found to be low in a large proportion of patients. Electrocardiographic (ECG) changes are common but are not associated with myocardial damage. When molecular end points were evaluated in 61 patients enrolled on a Phase II trial with romidepsin, response was associated with persistence of acetylated histone H3, suggesting that drug exposure is important in effective therapy with romidepsin. Future studies will endeavor to identify combination strategies to increase the efficacy both in resistant CTCL and in solid tumors and to identify biomarkers of response that will allow selection of patients most likely to benefit from the therapy.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
1744-8328
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
10
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
997-1008
pubmed:meshHeading
pubmed-meshheading:20645688-Antineoplastic Agents, pubmed-meshheading:20645688-Bone Marrow Diseases, pubmed-meshheading:20645688-Clinical Trials, Phase II as Topic, pubmed-meshheading:20645688-Depsipeptides, pubmed-meshheading:20645688-Fatigue, pubmed-meshheading:20645688-Gastrointestinal Diseases, pubmed-meshheading:20645688-Gene Targeting, pubmed-meshheading:20645688-Heart Diseases, pubmed-meshheading:20645688-Histone Deacetylase Inhibitors, pubmed-meshheading:20645688-Histone Deacetylases, pubmed-meshheading:20645688-Humans, pubmed-meshheading:20645688-Infection, pubmed-meshheading:20645688-Lymphoma, T-Cell, Cutaneous, pubmed-meshheading:20645688-Molecular Structure, pubmed-meshheading:20645688-Neoplasm Proteins, pubmed-meshheading:20645688-Neoplasms, pubmed-meshheading:20645688-Practice Guidelines as Topic
pubmed:year
2010
pubmed:articleTitle
Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors.
pubmed:affiliation
Medical Oncology Branch, SAIC-Frederick, NCI-Frederick, MA, USA.
pubmed:publicationType
Journal Article, Review, Research Support, Non-U.S. Gov't